Rein Therapeutics (NASDAQ:RNTX – Get Free Report) and Emmaus Life Sciences (OTCMKTS:EMMA – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, risk, profitability, analyst recommendations and dividends.
Valuation & Earnings
This table compares Rein Therapeutics and Emmaus Life Sciences”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Rein Therapeutics | N/A | N/A | -$49.87 million | ($1.96) | -0.57 |
| Emmaus Life Sciences | $12.45 million | 0.06 | -$7.49 million | ($0.12) | -0.08 |
Analyst Ratings
This is a summary of current recommendations and price targets for Rein Therapeutics and Emmaus Life Sciences, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Rein Therapeutics | 1 | 1 | 1 | 0 | 2.00 |
| Emmaus Life Sciences | 0 | 0 | 0 | 0 | 0.00 |
Rein Therapeutics currently has a consensus target price of $8.00, suggesting a potential upside of 614.29%. Given Rein Therapeutics’ stronger consensus rating and higher probable upside, equities analysts clearly believe Rein Therapeutics is more favorable than Emmaus Life Sciences.
Insider & Institutional Ownership
90.9% of Rein Therapeutics shares are owned by institutional investors. Comparatively, 7.4% of Emmaus Life Sciences shares are owned by institutional investors. 5.1% of Rein Therapeutics shares are owned by insiders. Comparatively, 35.0% of Emmaus Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Profitability
This table compares Rein Therapeutics and Emmaus Life Sciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Rein Therapeutics | N/A | -510.35% | -56.38% |
| Emmaus Life Sciences | -60.16% | N/A | -34.05% |
Risk & Volatility
Rein Therapeutics has a beta of 1.42, suggesting that its share price is 42% more volatile than the S&P 500. Comparatively, Emmaus Life Sciences has a beta of 9.32, suggesting that its share price is 832% more volatile than the S&P 500.
Summary
Emmaus Life Sciences beats Rein Therapeutics on 8 of the 13 factors compared between the two stocks.
About Rein Therapeutics
Rein Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky on August 6, 2001 and is headquartered in Austin, TX.
About Emmaus Life Sciences
Emmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally. The company's lead candidate is Endari, an L-glutamine oral powder to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older. It has a collaboration agreement with Kainos Medicine, Inc. for the preclinical development of Kainos' patented IRAK4 inhibitor (KM10544) as an anti-cancer drug. The company was formerly known as Emmaus Holdings, Inc. and changed its name to Emmaus Life Sciences, Inc. in September 2011. The company was founded in 2000 and is headquartered in Torrance, California.
Receive News & Ratings for Rein Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rein Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
